A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Overview

This article presents a protocol for a nicotinamide adenine dinucleotide (NADH)-coupled ATPase assay optimized for semi-high-throughput screening of small molecule myosin inhibitors. The assay is designed to be run in a 384-well microplate format, making it suitable for various ADP-producing enzymes.

Key Study Components

Area of Science

• Neuroscience
• Biochemistry
• Pharmacology

Background

• The assay is applicable to developing ATPase inhibitors.
• It serves as a probe for basic research and potential clinical compounds.
• The method avoids common artifacts and does not involve hazardous materials.
• Specific inhibitors for non-muscle myosin II are being developed for treating methamphetamine use disorder.

Purpose of Study

• To provide a reliable screening method for ATPase inhibitors.
• To facilitate research into non-muscle myosin II inhibitors.
• To optimize the assay for semi-high-throughput applications.

Methods Used

• NADH-coupled ATPase assay.
• 384-well microplate format.
• 20 µL total reaction volumes per well.
• Visual demonstrations to clarify technical details.

Main Results

• Successful adaptation of the assay for screening small molecule inhibitors.
• Demonstrated applicability to various ADP-producing enzymes.
• Potential for developing specific inhibitors for clinical use.
• Minimized handling of hazardous materials during the process.

Conclusions

• The optimized assay is effective for semi-high-throughput screening.
• It can be applied to a wide range of ATP-producing enzymes.
• Further research may lead to new therapeutic options for methamphetamine use disorder.

Frequently Asked Questions